Growing physician adoption and patient referrals for Casgevy are putting CRISPR Therapeutics (CRSP) back in focus, as the company reports a narrower Q1 2026 loss and highlights multiple gene editing milestones ahead.

CRISPR Therapeutics’ recent Q1 update and growing Casgevy uptake appear to be feeding into short term momentum, with a 1 day share price return of 5.32% and a 7 day share price return of 12.99%. However, the 90 day share price return is down 6.25%, and longer term performance remains mixed, with a 1 year total shareholder return of 53.29% but a 5 year total shareholder return that is down 48.67%.

If Casgevy’s traction has your attention and you want to see what else is moving in healthcare, now could be a good time to investigate 35 healthcare AI stocks

With the stock up strongly over the past year yet still trading below some intrinsic and analyst estimates, is CRISPR Therapeutics offering you a genuine valuation gap, or is the market already pricing in future growth?

Price to Book of 3x: Is it justified?

On a P/B basis, CRISPR Therapeutics trades at 3x book value, which looks expensive versus the broader US Biotechs sector but lower than closer peers.

P/B compares a company’s market value to its net assets, so for a pre profit biotech like CRISPR Therapeutics it effectively reflects what investors are willing to pay today for the current pipeline, cash, and intellectual property.

Relative signals are mixed. The stock screens as expensive versus the US Biotechs industry average P/B of 2.6x. However, it looks cheaper than a narrower peer set that averages 7.1x, which suggests investors may be assigning less aggressive expectations than some direct comparables even though the sector as a whole prices it at a premium.

Result: Price-to-book of 3x (ABOUT RIGHT)

However, you also need to weigh execution and funding risks, given CRISPR Therapeutics is still loss making and relies heavily on future cash flows from its pipeline.

Another way to look at value

The earlier P/B check suggested CRISPR Therapeutics is roughly in line with what you might expect for a pre profit biotech. The SWS DCF model, however, points in a different direction, with an estimated future cash flow value of $179.15 per share versus the current $56.38 price. This implies the stock trades at a large discount. The key question is whether this represents a genuine opportunity or whether the cash flow assumptions are simply too optimistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism around Casgevy and caution around execution and funding, this is a moment to review the data yourself and act before sentiment shifts again. To see the full balance of potential upsides and areas of concern, go through the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Casgevy has put gene editing on your radar, do not stop there. Broaden your watchlist now so you are not reacting after the market moves.

• Target potential mispricings by scanning 46 high quality undervalued stocks, which combine solid fundamentals with room for the market to reassess expectations.
• Prioritise staying power by reviewing solid balance sheet and fundamentals stocks screener (46 results), where stronger finances can support businesses through tougher periods.
• Get ahead of the crowd by studying screener containing 22 high quality undiscovered gems, which have quality metrics but sit outside the usual spotlight.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.